Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.

被引：0
|
作者：
Souglakos, J [1 ]
Kouroussis, C [1 ]
Ziras, N [1 ]
Malamos, N [1 ]
Potamianou, A [1 ]
Mavroudis, D [1 ]
Kakolyris, S [1 ]
Androulakis, N [1 ]
Vardakis, N [1 ]
Georgoulias, V [1 ]
机构：
[1] Greek Cooperat Grp GI Tumors, Heraklion, Greece
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215P
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [21] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [22] A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
    Fisher, GA
    Cho, CD
    Halsey, JZ
    Advani, RH
    Yuen, AR
    Lum, BL
    Sikic, BI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S63 - S63
  • [23] Bolus 5-fluorouracil plus leucovorin (FU-LV) in first-line treatment of advanced colorectal cancer.
    López, A
    Sánchez, J
    Gómez-Aldaraví, JL
    Fernández-Aramburo, A
    Yustos, A
    Romero, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S75 - S75
  • [24] Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (541.1) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase
    Souglakos, J
    Ziras, N
    Polyzos, A
    Athanasiadis, A
    Kakolyris, S
    Giannakakis, T
    Tselepatiotis, E
    Kalbakis, K
    Vardakis, N
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 253S - 253S
  • [25] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [26] CPT-11/5-fluorouracil(5-FU)/leucchorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselectecl advanced colorectal cancer (ACC) patients.
    Garufi, C.
    Torsello, A.
    Campanella, C.
    Ettorre, G. M.
    Vennarecci, G.
    Melucci, E.
    Zeuli, M.
    Sperduti, I.
    Gelibter, A.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] QoL and resource use analysis of tegafur-uraciI/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study.
    Sizer, B.
    Makris, A.
    Barone, C.
    Mainwaring, P.
    Eggleton, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 178S - 178S
  • [28] Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
    B Neri
    P Pantaleo
    E Giommoni
    R Grifoni
    C Paoletti
    V Rotella
    D Pantalone
    A Taddei
    A Mercatelli
    P Tonelli
    British Journal of Cancer, 2007, 96 : 1043 - 1046
  • [29] Oxaliplatin (L-OHP) combined with continous infusion 5-fluorouracil (5-FU) and folinic acid (FA) based regimen in advanced colorectal cancer patients, confirmatory data on efficacy and toxicity
    Bochicchio, AM
    Capobianco, AML
    Coccaro, M
    Colasuonno, L
    Di Leo, P
    Galasso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 64 - 64
  • [30] Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.
    Iqbal, S
    Cole, S
    Yang, D
    Lara, PN
    Gumerlock, PH
    Shibata, S
    Synold, T
    Doroshow, JH
    Gandara, D
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 141S - 141S
12345